A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies

Completed · Phase 1/Phase 2

Conditions studied: Lymphoma, Leukemia, Multiple Myeloma

In brief

This study evaluated safety, tolerability, pharmacokinetics and preliminary anti-leukemic or anti-tumor activity of LBH589B in adult patients with advanced hematological malignancies

Key facts

Study ID

NCT00621244

Run by

Novartis Pharmaceuticals

People needed

175

Starts

2003-03-01

Expected to finish

2009-12-03

Last updated by the study team

2021-01-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients (≥18 years old) with advanced hematological malignancies who relapsed after or are refractory to standard therapy, or for which no standard therapy existed; or, were considered inappropriate candidates for standard therapy
• World Health Organization (WHO) performance status ≤ 2
• Patients who met protocol-specified hematologic and non-hematologic laboratory values
• Patients with adequate liver and renal function

You may not qualify if…

• Concurrent brain metastases or leukemic infiltration of the cerebrospinal fluid
• Peripheral neuropathy ≥ CTCAE grade 2
• Unresolved diarrhea ≥ CTCAE grade 2
• Concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study, including impaired heart function or clinically significant heart disease, and impaired gastrointestinal function or disease that significantly altered aborption of LBH589
• Female patients who were pregnant or breast feeding
• Patients who were unwilling to use an effective method of birth control
• Patients who took medications specified by the protocol as prohibited for administration in combination with LBH589
• Patients with another primary malignancy that required active intervention or were clinically significant

Where it is running

• Georgia Health Sciences University Dept.ofMedicalCollegeOfGeorgia — Augusta, Georgia, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• MD Anderson Cancer Center/University of Texas — Houston, Texas, United States
• Novartis Investigative Site — Parkville, Victoria, Australia
• Novartis Investigative Site — Prahran, Victoria, Australia
• Novartis Investigative Site — Frankfurt/M, Germany
• Novartis Investigative Site — Mainz, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.